(Q38168144)

30 August 2017

title

Macitentan: first global approval (English)

1 reference

30 August 2017

1 reference

ChEBI release 2020-05-28

2

Kate McKeage

1 reference

30 August 2017

Trina Patel

1

1 reference

30 August 2017

publication date

1 January 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

74

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

127-133

1 reference

Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0156-6

Pathways in pulmonary arterial hypertension: the future is here.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0156-6

The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0156-6

Macitentan and morbidity and mortality in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0156-6

Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0156-6

Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0156-6

Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0156-6

Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0156-6

Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0156-6

Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0156-6

Macitentan: entry-into-humans study with a new endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0156-6

Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0156-6

Pharmacokinetics of macitentan in caucasian and Japanese subjects: the influence of ethnicity and sex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0156-6

Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0156-6

Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0156-6

Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0156-6

Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24297706

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Macitentan slows down the dermal fibrotic process in systemic sclerosis: in vitro findings

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24297706

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24297706

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40265-013-0156-6

1 reference

Dimensions Publication ID

30 August 2017

1044068518

0 references

1 reference